Two New Studies Demonstrate T2Candida’s Advantages over Current Diagnostic Testing Biotech Investing
Catalyst Biosciences Announces Positive Top-Line Data from Phase 1/2 Study of Subcutaneous CB Biotech Investing
Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update Biotech Investing
Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA Pharmaceutical Investing
Onconova Therapeutics Announces Pricing of $8.7 Million Underwritten Public Offering Biotech Investing
